Accordingly, Novartis’ sabatolimab is under early-phase evaluation in combination with radiotherapy and PD-1 blockade, offering a low-toxicity, high-efficacy neoadjuvant strategy for locally advanced HNSCC [89,90]. This evidence concerns the gene RPL17 and head and neck squamous cell carcinoma.